Jefferies Comments On ViroPharma's Cinryze Approval In Europe

According to Jefferies, VitoPharma VPHM announced that the European Medicines Agency approved Cinryze in Europe for the treatment of hereditary angioedema (HAE). Jefferies said that it remains confident in $400m+ U.S. Cinryze prophylactic HAE sales by 2015. “Cetor is only selling in a few European countries and we believe it has generated minimal sales, whereas with a broad European label, we continue to believe there could be upside to our peak sales estimate of $68m in international Cinryze sales by 2016, even with an expected European price for Cinryze that is 40-50% of the U.S. price.” VitoPharma closed yesterday at $17.54.